Browsing: Federal
New Aimed Alliance Article, Published in Journal of Pharmaceutical Policy and Practice, Calls for Preservation of REMS Program
Aimed Alliances Urges Congress to Keep the Current Risk Evaluation and Mitigation Strategies (REMS) Program Intact…
Aimed Alliance Testifies at FDA Committee Hearing on Novel New Drug
Aimed Alliance’s Director of Medical Affairs, Dr. Shannon Ginnan, testified on an innovative buprenorphine subdermal…
Aimed Alliance Signs on to Coalition for Accessible Treatments Letter
Aimed Alliance has signed on to the Coalition for Accessible Treatments’ letter commenting on the…
CMS’s “Creative Accounting” for Insurance Co-Ops Comes under Question
The Centers for Medicare and Medicaid Services (CMS) was scrutinized by two senate committee leaders…
White House Confirms Steep 2016 Obamacare Premium Hikes
Report Highlights Need for Policy Solutions to Improve Industry Shortcomings Washington, D.C. – The Obama…
Aimed Alliance Signs on to “I Am Essential” Coalition Letter
Aimed Alliance has signed on to the “I Am Essential” coalition’s letter, urging the United…
Aimed Alliance Submits Comment to FDA on Approval of Generic Chronic Dry Eye Med
Earlier today, Aimed Alliance’s Director of Public Policy, Stacey L. Worthy, submitted a comment to…
Aimed Alliance Presents Testimony Urging FDA Panel’s Approval of Novel Treatment
Today, Aimed Alliance presented testimony before a joint meeting of the U.S. Food and Drug…
FDA Releases Much-Anticipated Guidelines on Biosimilar Naming
This week, the U.S. Food and Drug Administration (FDA) released its much-anticipated guidelines on the…